HLB Genex
HLB제넥스 · 187420
Health Care Pharmaceuticals · KOSDAQ
Market cap US$50M (₩69B)
Overview
HLB Genex develops and produces custom enzymes and bio-healthcare ingredients, for example, a catalase enzyme used to break down hydrogen peroxide in semiconductor and textile water-treatment processes, and a lactase enzyme used to make a probiotic ingredient found in breast milk.
Its products reach customers across environmental, food, and cosmetics industries, as well as health-supplement and pharmaceutical supply chains. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates across three main lines: industrial specialty enzymes, bio-healthcare materials, and microbiome-enzyme product development.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$19.6M
- FY2024US$25.7M
- FY2025US$31.4M
Operating profit
- FY2023−US$6.9M
- FY2024−US$1.4M
- FY2025US$873.7K
Net income
- FY2023−US$523K
- FY2024−US$13M
- FY2025US$16.6M
Key ratios (FY2025)
Why it matters
HLB Genex has a subsidiary, HLB Neurotrove, founded as a KAIST faculty startup, which conducts early-stage drug research targeting neurological diseases such as dystonia and Parkinson's disease.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?